For research use only. Not for therapeutic Use.
XL-228（Cat No.:I005377）is an investigational oral compound classified as a kinase inhibitor, targeting multiple pathways involved in cancer cell proliferation and survival. It is designed to inhibit various receptor tyrosine kinases and other enzymes, disrupting signaling cascades that promote tumor growth. XL-228 has shown promise in preclinical studies and early-phase clinical trials for treating hematologic malignancies and solid tumors. Common side effects may include fatigue, nausea, and potential liver function changes. Ongoing research aims to evaluate its efficacy and safety profile compared to existing therapies.
| Catalog Number | I005377 |
| CAS Number | 898280-07-4 |
| Synonyms | 4-N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-N-[(3-propan-2-yl-1,2-oxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| Molecular Formula | C₂₂H₃₁N₉O |
| Purity | ≥95% |
| Target | Aurora Kinase; Bcr-Abl; IGF-1R; Src |
| Solubility | 10 mM in DMSO |
| Storage | Store at -20°C |
| IC50 | 3 nM (Aurora A Kinase); 5 nM (Ki, Abl) |
| IUPAC Name | 4-N-(5-cyclopropyl-1H-pyrazol-3-yl)-6-(4-methylpiperazin-1-yl)-2-N-[(3-propan-2-yl-1,2-oxazol-5-yl)methyl]pyrimidine-2,4-diamine |
| InChI | InChI=1S/C22H31N9O/c1-14(2)17-10-16(32-29-17)13-23-22-25-19(24-20-11-18(27-28-20)15-4-5-15)12-21(26-22)31-8-6-30(3)7-9-31/h10-12,14-15H,4-9,13H2,1-3H3,(H3,23,24,25,26,27,28) |
| InChIKey | ALKJNCZNEOTEMP-UHFFFAOYSA-N |
| SMILES | CC(C)C1=NOC(=C1)CNC2=NC(=CC(=N2)N3CCN(CC3)C)NC4=NNC(=C4)C5CC5 |
| Reference | <p style=/line-height:25px/> |
